Abridge CEO Dr. Shiv Rao says new Nvidia and Eli Lilly partnerships aim to advance clinical AI

Abridge CEO Dr. Shiv Rao said the company has launched new partnership discussions involving Nvidia and Eli Lilly, framing the effort as part of a broader push to apply AI to healthcare use cases. Rao made the remarks during an interview tied to NYSE Live, where he discussed how the collaborations could support Abridge’s work delivering AI-generated clinical summaries and other clinician-facing capabilities.

Rao’s comments, as captured in the video listing on Yahoo Finance, focused on “new partnerships” and did not specify the scope of each relationship, the technologies involved, or whether the collaborations are research, commercial deployment, or both. The interview format also means the public disclosure is limited to high-level statements rather than contractual or performance details.

Nvidia’s role in many healthcare AI programs typically relates to the compute layer, including the training and deployment of large AI models on graphics processing units. In life sciences, companies such as Eli Lilly often evaluate AI tools for tasks ranging from clinical documentation to support for research workflows. However, the interview posting does not provide enough detail to determine which parts of these value chains the partners intend to pursue together.

Abridge, for its part, has positioned itself around using AI to assist clinical communication. While the Yahoo Finance listing does not include technical or product specifications in text form, the company’s public identity in the market has centered on transforming unstructured conversations between clinicians and patients into structured outputs that can reduce documentation burden.

The Eli Lilly partnership angle indicates that at least some external stakeholders are exploring AI integration beyond standalone medical documentation tools, potentially aligning with how large pharmaceutical companies think about data capture, evidence generation, and operational efficiency. Still, the interview text does not disclose whether Lilly would use Abridge tools internally, evaluate them in trials, or pursue a broader ecosystem relationship.

Given the limited information made available in the video listing, key commercial and operational questions remain unanswered. The posting does not disclose whether either partnership includes financial terms, exclusivity, named product deployments, or timelines. It also does not clarify the specific AI model approach, governance approach, or how outputs would be validated in clinical contexts.

For the sector, the remarks fit a wider pattern in healthcare AI: hyperscalers and semiconductor suppliers are increasingly partnering with healthcare-focused software vendors, while large pharma firms explore ways to incorporate AI-generated data into real-world operations and long-running research programs. The emphasis on multiple partners also reflects how companies assemble AI stacks across compute, software, and domain workflows.